Celcuity (CELC) Amortization of Deferred Charges (2021 - 2026)
Celcuity's (CELC) quarterly Amortization of Deferred Charges came in at $1.3 million in Q4 2025, up 130.67% YoY from $551000.0 in Q4 2024, and up 63.37% on a QoQ basis from $778000.0 in Q3 2025.
Analysis
Celcuity (CELC) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Celcuity (CELC) has 5 years of Amortization of Deferred Charges data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Amortization of Deferred Charges rose 130.67% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (up 135.69% YoY) and the FY2025 annual result came in at $3.1 million, up 135.69% from the prior year.
- Amortization of Deferred Charges rose to $1.3 million in Q4 2025, from $778000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $1.3 million in Q4 2025 to a low of $57004.0 in Q1 2023.
- A 5-year average of $293986.6 and a median of $99828.5 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges sank 42.81% — and 2024, when it jumped 763.46%.
- Tracing CELC's Amortization of Deferred Charges over 5 years: stood at $94460.0 in 2021, then gained by 18.12% to $111573.0 in 2022, then plunged by 42.81% to $63813.0 in 2023, then jumped by 763.46% to $551000.0 in 2024, then soared by 130.67% to $1.3 million in 2025.
- The last three Amortization of Deferred Charges figures came in at $1.3 million (Q4 2025), $778000.0 (Q3 2025), and $537000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | 778,000.00 |
| Jun 30, 2025 | 537,000.00 |
| Mar 31, 2025 | 551,000.00 |
| Dec 31, 2024 | 551,000.00 |
| Sep 30, 2024 | 478,000.00 |
| Jun 30, 2024 | 237,000.00 |
| Mar 31, 2024 | 65,000.00 |
| Dec 31, 2023 | 63,813.00 |
| Sep 30, 2023 | 61,721.00 |
| Jun 30, 2023 | 59,214.00 |
| Mar 31, 2023 | 57,004.00 |
| Dec 31, 2022 | 111,573.00 |
| Sep 30, 2022 | 104,645.00 |
| Jun 30, 2022 | 84,527.00 |
| Mar 31, 2022 | 95,012.00 |
| Dec 31, 2021 | 94,460.00 |
| Sep 30, 2021 | 91,790.00 |